Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae

Journal of Bioscience and Bioengineering

Volumn 119, Issue 1, 2015, Pages 19-27

  Nguyen, Ngoc Luong ^a   So, Kum Kang ^a   Kim, Jung Mi ^b   Kim, Sae Hae ^a   Jang, Yong Suk ^a   Yang, Moon Sik ^a   Kim, Dae Hyuk ^a  

^a Chonbuk National University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Baker's yeast; Dengue virus; Domain III of the dengue envelope protein; M cell specific peptide ligand; Oral feeding

Indexed keywords

CYTOLOGY; ELECTROPHORESIS; ESCHERICHIA COLI; GENE ENCODING; GENE EXPRESSION; LIGANDS; PEPTIDES; VACCINES; VIRUSES; YEAST;

BAKER'S YEAST; DENGUE VIRUS; ENVELOPE PROTEINS; ORAL FEEDING; PEPTIDE LIGAND;

RECOMBINANT PROTEINS;

AMYLASE; AMYLASE A1; EPITOPE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIGAND; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN TET EDIII CO1; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; HYBRID PROTEIN; VIRUS ANTIGEN; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DENGUE VIRUS; DRUG BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISOME; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE; GENE EXPRESSION; GPD GENE; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NORTHERN BLOTTING; PEYER PATCH; PLASMID; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RICE; SACCHAROMYCES CEREVISIAE; WESTERN BLOTTING; CHEMISTRY; CLASSIFICATION; CYTOLOGY; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSFORMATION; GENETICS; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

DENGUE VIRUS; ESCHERICHIA COLI; SACCHAROMYCES CEREVISIAE;

ADMINISTRATION, ORAL; ANTIGENS, VIRAL; DENGUE VIRUS; EPITOPES; GENETIC VECTORS; IMMUNITY, MUCOSAL; LIGANDS; ORYZA SATIVA; PEYER'S PATCHES; PLASMIDS; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; TRANSFORMATION, GENETIC; VIRAL VACCINES;

EID: 84927178513     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2014.06.005     Document Type: Article

References (51)

1. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5:518-528.
2. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., Hunsperger E., Kroeger A., Margolis H.S., Martinez E., other 5 authors Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010, 8:S7-S16.
3. Trent D., Shin J., Hombach J., Knezevic I., Minor P. WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. Vaccine 2010, 28:8246-8255.
4. Pang T., Cardosa M.J., Guzman M.G. Of cascades and perfect storms: the immuno-pathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol. Cell Biol. 2007, 85:43-45.
5. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 2011, 11:532-543.
6. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J.Virol. 2001, 75:7769-7773.
7. Thullier P., Demangel C., Bedouelle H., Megret F., Jouan A., Deubel V., Mazie J.C., Lafaye P. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J.Gen. Virol. 2001, 82:1885-1892.
8. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., Schlesinger J.J., Wright P.J., Young P., Van Regenmortel M.H., Deubel V. Use of recombinant fusion proteins and monoclonal-antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992, 187:480-491.
9. Chen Y.P., Maguire T., Marks R.M. Demonstration of binding of dengue virus envelope protein to target cells. J.Virol. 1996, 70:8765-8772.
10. Simmons M., Nelson W.M., Wu S.J.L., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 1998, 58:655-662.
11. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 2001, 65:159-161.
12. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., Khanna N. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 2008, 79:353-363.
13. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Lien S.P., Yueh A., Hsiao K.N., Lai L.W., other 3 authors Anovel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009, 11:288-295.
14. Block O.K., Rodrigo W.W., Quinn M., Jin X., Rose R.C., Schlesinger J.J. Atetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 2010, 28:8085-8094.
15. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., Putnak J.R., Ivy J.M., McDonell M., Bignami G.S., other 5 authors Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28:2705-2715.
16. Chiang C.Y., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Chong P., Leng C.H., Chen H.W. Anovel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 2011, 6:e23319.
17. Nguyen N.L., Kim J.M., Park J.A., Park S.M., Jang Y.S., Yang M.S., Kim D.H. Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae. Protein Expr. Purif. 2013, 88:235-242.
18. Yuki Y., Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev. Vaccines 2009, 8:1083-1097.
19. Lycke N. Recent progress in mucosal vaccine development: potential and limitation. Nat. Rev. Immunol. 2012, 12:592-605.
20. Fujkuyama Y., Tokuhara D., Kataoka K., Gilbert R.S., McGhee J.R., Yuki Y., Kiyono H., Fujihashi K. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev. Vaccines 2012, 11:367-379.
21. Wang L., Coppel R.L. Oral vaccine delivery: can it protect against non-mucosal pathogens?. Expert Rev. Vaccines 2008, 7:729-738.
22. Kim S.H., Seo K.W., Kim J., Lee K.Y., Jang Y.S. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J.Immunol. 2010, 185:5787-5795.
23. Cerutti A., Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity 2008, 28:740-750.
24. Kyd J.M., Cripps A.W. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 2008, 26:6221-6224.
25. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., Kadokura K., Tobe T., Fujimura Y., Kawano S., other 12 authors Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
26. Nochi T., Yuki Y., Matsumura A., Mejima M., Terahara K., Kim D.Y., Fukuyama S., Iwatsuki-Horimoto K., Kawaoka Y., Kohda T., other 3 authors Anovel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J.Exp. Med. 2007, 204:2789-2796.
27. Kim J.M., Jung D.I., Eom Y.J., Park S.M., Yoo H.S., Jang Y.S., Yang M.S., Kim D.H. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Biosci. Biotechnol. Biochem. 2010, 74:1362-1367.
28. Shin Y.M., Kwon T.H., Kim K.S., Chae K.S., Kim D.H., Kim J.H., Yang M.S. Enhanced iron uptake of Saccharomyces cerevisiae by heterologous expression of a tadpole ferritin gene. Appl. Environ. Microbiol. 2001, 67:1280-1283.
29. Kim T.G., Kim M.Y., Yang M.S. Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants. Biotechnol. Bioprocess Eng. 2009, 14:725-730.
30. Lim J.G., Kim J.A., Chung H.J., Kim T.G., Kim J.M., Lee K.R., Park S.M., Yang M.S., Kim D.H. Expression of functional pentameric heat-labile enterotoxin B subunit of Escherichia coli in Saccharomyces cerevisiae. J.Microbiol. Biotechnol. 2009, 19:502-510.
31. Gietz R.D., Schiestl R.H., Willems A.R., Woods R.A. Studies on the transformation of intact yeast-cells by the LiAc/S-DNA/Peg procedure. Yeast 1995, 11:355-360.
32. Park S.M., Mo A.Y., Jang Y.S., Lee J.H., Yang M.S., Kim D.H. Expression of a functional human tumor necrosis factor-alpha (hTNF-alpha) in yeast Saccharomyces cerevisiae. Biotechnol. Bioprocess Eng. 2004, 9:292-296.
33. Mo A.Y., Park S.M., Kim Y.S., Yang M.S., Kim D.H. Expression of fungal phytase on the cell surface of Saccharomyces cerevisiae. Biotechnol. Bioprocess Eng. 2005, 10:576-581.
34. Lim Y.Y., Park E.H., Kim J.E., Park S.M., Jang H.S., Park Y.J., Yoon S.W., Yang M.S., Kim D.H. Enhanced and targeted expression of fungal phytase in Saccharomyces cerevisiae. J.Microbiol. Biotechnol. 2001, 11:915-921.
35. Ciplys E., Samuel D., Juozapaitis M., Sasnauskas K., Slibinskas R. Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae. Microb. Cell Fact. 2011, 10:37.
36. Jabbar M.A., Nayak D.P. Signal-processing, glycosylation, and secretion of mutant hemagglutinins of a human influenza-virus by Saccharomyces cerevisiae. Mol. Cell. Biol. 1987, 7:1476-1485.
37. Martinet W., Saelens X., Deroo T., Neirynck S., Contreras R., Jou W.M., Fiers W. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem. 1997, 247:332-338.
38. Sakamoto S., Ide T., Tokiyoshi S., Nakao J., Hamada F., Yamamoto M., Grosby J.A., Ni Y.J., Kawai A. Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells. Vaccine 1999, 17:205-218.
39. Wen D.Z., Ding M.X., Schlesinger M.J. Expression of genes encoding vesicular stomatitis and sindbis virus glycoproteins in yeast leads to formation of disulfide-linked oligomers. Virology 1986, 153:150-154.
40. Scorer C.A., Buckholz R.G., Clare J.J., Romanos M.A. The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast Pichia pastoris. Gene 1993, 136:111-119.
41. Khanam S., Etemad B., Khanna N., Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 2006, 74:266-277.
42. Konishi E., Kosugi S., Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24:2200-2207.
43. Khanam S., Pilankatta R., Khanna N., Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27:6011-6021.
44. Raviprakash K., Apt D., Brinkman A., Skinner C., Yang S., Dawes G., Ewing D., Wu S.J., Bass S., Punnonen J., Porter K. Achimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006, 353:166-173.
45. Chen S., Yu M., Jiang T., Deng Y., Qin C., Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007, 26:361-367.
46. Halstead S.B. More dengue, more questions. Emerg. Infect. Dis. 2005, 11:740-741.
47. Kim T.G., Kim M.Y., Huy N.X., Kim S.H., Yang M.S. Mcell-targeting ligand and consensus dengue virus envelope protein domain III fusion protein production in transgenic rice calli. Mol. Biotechnol. 2013, 54:880-887.
48. Silin D.S., Lyubomska O.V., Jirathitikal V., Bourinbaiat A.S. Oral vaccination: where we are?. Expert Opin. Drug Del. 2007, 4:323-340.
49. Kim J.M., Park S.M., Kim J.A., Park J.A., Yi M.H., Kim N.S., Bae J.L., Park S.G., Jang Y.S., Yang M.S., Kim D.H. Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against challenge by Actinobacillus pleuropneumoniae. Clin. Vaccine Immunol. 2011, 18:2168-2177.
50. Liljeqvist S., Stahl S., Andreoni C., Binz H., Uhlen M., Murby M. Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J.Immunol. Methods 1997, 210:125-135.
51. Yanagibashi T., Hosono A., Oyama A., Tsuda M., Hachimura S., Takahashi Y., Itoh K., Hirayama K., Takahashi K., Kaminogawa S. Bacteroides induce higher IgA production than Lactobacillus by increasing activation-induced cytidine deaminase expression in B cells in murine Peyer's patches. Biosci. Biotechnol. Biochem. 2009, 73:372-377.